What is the 13F Pro Quality Score for SYRE?

13F Pro ranks Spyre Therapeutics, Inc. (SYRE) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SYRE's current score at https://13fpro.ai/research/SYRE (free sign-up required for the full ranking).

Which hedge funds own the most SYRE stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of SYRE include FMR, BlackRock,, RTW INVESTMENTS,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/SYRE as soon as new 13F filings post.

Where does 13F Pro source SYRE data?

All Spyre Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Spyre Therapeutics, Inc. files with the SEC under CIK 1636282. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SYRE in?

Spyre Therapeutics, Inc. (SYRE) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SYRE research updated on 13F Pro?

SYRE's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Spyre Therapeutics, Inc.(SYRE)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1636282 SYRE stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

SYRE Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Spyre Therapeutics, Inc. (SYRE), a Healthcare sector company. SYRE is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Spyre Therapeutics, Inc. reports net income of $-69.0M, free cash flow of $-57.4M. Top institutional holders of SYRE by reported 13-F value include FMR, BlackRock,, RTW INVESTMENTS,, based on the most recent SEC filings. SYRE trades on the Nasdaq exchange and files with the SEC under CIK 1636282. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SYRE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Spyre Therapeutics, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-69.0M

Free Cash Flow

Q1 2026

$-57.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$0.00FY 2025

FY20 $0.00FY21 $18.7MFY24 $0.00FY25 $0.00

Net Income

+25.4% YoY

$-155.2MFY 2025

FY20 $-80.9MFY21 $-65.8MFY24 $-208.0MFY25 $-155.2M

Operating Income

-0.5% YoY

$-209.6MFY 2025

FY20 $-81.5MFY21 $-65.6MFY24 $-208.6MFY25 $-209.6M

EPS (Diluted)

—FY 2025

FY20 $-0.06FY21 $-1.00FY24 —FY25 —

Total Assets

+27.8% YoY

$777.8MFY 2025

FY20 $161.6MFY21 $109.9MFY24 $608.5MFY25 $777.8M

Op. Cash Flow

-7.5% YoY

$-169.3MFY 2025

FY20 $-75.8MFY21 $-53.7MFY24 $-157.4MFY25 $-169.3M

Metric	FY 2025	FY 2024	FY 2021	FY 2020	FY 2019	FY 2018
Revenue	$0.00	$0.00 -100.0%	$18.7M	$0.00	$0.00 -100.0%	$3.9M
Net Income	$-155.2M +25.4%	$-208.0M -216.1%	$-65.8M +18.7%	$-80.9M -3.4%	$-78.3M -76.5%	$-44.3M
Operating Income	$-209.6M -0.5%	$-208.6M -217.7%	$-65.6M +19.4%	$-81.5M -1.4%	$-80.3M -76.7%	$-45.5M
EPS (Diluted)	—	—	$-1.00 -1546.1%	$-0.06	—	—
Total Assets	$777.8M +27.8%	$608.5M +453.5%	$109.9M -32.0%	$161.6M +94.3%	$83.2M +7.0%	$77.7M
Operating Cash Flow	$-169.3M -7.5%	$-157.4M -193.0%	$-53.7M +29.1%	$-75.8M -15.3%	$-65.7M -104.1%	$-32.2M

AI Insight: SYRE Financial Trends

Spyre shows volatile burn profile with equity cushion remaining strong at $671M despite eight consecutive quarters of losses.

• Net losses ranged from $11M in Q3 2025 to $69M in Q3 2024 and Q1 2026, showing high quarterly volatility.

• Equity base strengthened from $374M in Q2 2024 to $671M in Q1 2026 despite ongoing losses.

• Operating cash flow burn averaged $43M per quarter over the eight-quarter period.

⚠ Net loss widened from $11M in Q3 2025 to $69M in Q1 2026, reversing temporary improvement trend.

⚠ Operating cash flow deteriorated from $37M burn in Q3 2025 to $57M burn in Q1 2026.

AI Insight: SYRE Ratio Trends

SYRE's profitability metrics remain deeply negative with ROE at -41.1% and ROIC at -27.2% in Q1 2026.

• ROE improved from -84.3% in Q3 2024 to -9.8% in Q3 2025 before deteriorating to -41.1% in Q1 2026.

• ROIC showed modest improvement from -67.7% in Q3 2024 to -27.2% in Q1 2026.

• ROA declined from -8.9% in Q3 2025 to -36.1% in Q1 2026, reversing prior improvement trend.

⚠ Profitability volatility with ROE swinging from -9.8% to -41.1% across recent quarters indicates unstable operations.

⚠ Missing operating margin and net profit margin data limits visibility into core operational performance drivers.

Get alerted when SYRE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Spyre Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SYRE

FMR LLC
$594.2M11,781,024 sh
BlackRock, Inc.
$278.5M5,521,221 sh
RTW INVESTMENTS, LP
$210.4M4,171,996 sh
Fairmount Funds Management LLC
$202.7M4,018,101 sh
PERCEPTIVE ADVISORS LLC
$190.8M3,783,225 sh
VR Adviser, LLC
$185.9M3,685,448 sh
VANGUARD CAPITAL MANAGEMENT LLC
$154.2M3,057,401 sh
DRIEHAUS CAPITAL MANAGEMENT LLC
$140.8M2,790,785 sh
STATE STREET CORP
$131.5M2,607,031 sh
Paradigm Biocapital Advisors LP
$98.7M1,957,266 sh

Fund	Value	Shares
FMR LLC	$594.2M	11,781,024
BlackRock, Inc.	$278.5M	5,521,221
RTW INVESTMENTS, LP	$210.4M	4,171,996
Fairmount Funds Management LLC	$202.7M	4,018,101
PERCEPTIVE ADVISORS LLC	$190.8M	3,783,225
VR Adviser, LLC	$185.9M	3,685,448
VANGUARD CAPITAL MANAGEMENT LLC	$154.2M	3,057,401
DRIEHAUS CAPITAL MANAGEMENT LLC	$140.8M	2,790,785
STATE STREET CORP	$131.5M	2,607,031
Paradigm Biocapital Advisors LP	$98.7M	1,957,266

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SYRE on your watchlist

Track score changes the day Spyre Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SYRE a good stock to buy?

13F Pro's AI-powered analysis of Spyre Therapeutics, Inc. (SYRE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SYRE are available on the SYRE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SYRE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SYRE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Spyre Therapeutics, Inc.'s investment landscape.